Compare Pfizer Inc (PFE) vs TeraWulf Inc (WULF) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

TeraWulf (WULF) trades at $18.86, up 3.85% today, amid volatile AI infrastructure sector movements. The stock shows bearish technical signals with negative earnings trends, having missed Q1-Q3 2025-2026 EPS estimates. Fundamentally, the company reported a net loss of $661.42M on $168.46M revenue in 2025, though it secured a significant 20-year, $19B deal with Anthropic for AI data center capacity.

Despite unanimous analyst buy ratings and a $37.22 consensus price target suggesting 97% upside, WULF faces execution risks from high cash burn and negative margins. The Anthropic partnership offers long-term revenue potential but requires substantial capital investment amid competitive and regulatory pressures in the AI infrastructure space.